249 related articles for article (PubMed ID: 21867536)
1. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
[TBL] [Abstract][Full Text] [Related]
2. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
3. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.
Hodgson MC; Vanostran G; Alghamdi S; Poppiti RJ; Agoulnik AI; Agoulnik IU
PLoS One; 2013; 8(4):e60455. PubMed ID: 23593223
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
6. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
7. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
[TBL] [Abstract][Full Text] [Related]
8. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
Lozy F; Cai-McRae X; Teplova I; Price S; Reddy A; Bhanot G; Ganesan S; Vazquez A; Karantza V
Autophagy; 2014 Apr; 10(4):662-76. PubMed ID: 24492513
[TBL] [Abstract][Full Text] [Related]
9. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
10. IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development.
Jones RA; Watson KL; Campbell CI; Moorehead RA
PLoS One; 2014; 9(9):e108781. PubMed ID: 25259518
[TBL] [Abstract][Full Text] [Related]
11. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.
Campbell CI; Petrik JJ; Moorehead RA
Mol Cancer; 2010 Sep; 9():235. PubMed ID: 20825649
[TBL] [Abstract][Full Text] [Related]
13. Chronic oral exposure to bisphenol A results in a nonmonotonic dose response in mammary carcinogenesis and metastasis in MMTV-erbB2 mice.
Jenkins S; Wang J; Eltoum I; Desmond R; Lamartiniere CA
Environ Health Perspect; 2011 Nov; 119(11):1604-9. PubMed ID: 21988766
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis.
Zhao H; Cui Y; Dupont J; Sun H; Hennighausen L; Yakar S
Cancer Res; 2005 Aug; 65(15):6864-73. PubMed ID: 16061670
[TBL] [Abstract][Full Text] [Related]
15. Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues.
Ma Z; Parris AB; Howard EW; Shi Y; Yang S; Jiang Y; Kong L; Yang X
Carcinogenesis; 2018 Oct; 39(10):1264-1273. PubMed ID: 30107476
[TBL] [Abstract][Full Text] [Related]
16. In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk.
Ma Z; Parris AB; Howard EW; Davis M; Cao X; Woods C; Yang X
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32353937
[TBL] [Abstract][Full Text] [Related]
17. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
20. Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer.
Dearth RK; Delgado DA; Hiney JK; Pathiraja T; Oesterreich S; Medina D; Dees WL; Lee AV
Cancer Prev Res (Phila); 2010 Mar; 3(3):312-21. PubMed ID: 20145191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
